Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements - Narrative (Details)

v3.24.3
Fair Value Measurements - Narrative (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Mar. 28, 2024
USD ($)
shares
Nov. 06, 2024
USD ($)
shares
Sep. 30, 2024
USD ($)
$ / shares
shares
Sep. 30, 2023
USD ($)
Dec. 31, 2022
USD ($)
Sep. 30, 2024
USD ($)
$ / shares
shares
Sep. 30, 2023
USD ($)
Jun. 30, 2024
USD ($)
$ / shares
Mar. 31, 2024
$ / shares
Dec. 31, 2023
USD ($)
Jun. 30, 2023
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Closing stock price (in dollars per share) | $ / shares     $ 9.50     $ 9.50   $ 12.47 $ 21.75    
Net proceeds from the sale     $ (36,025) $ 0   $ (148,071) $ 0        
Level 3                      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Initial valuation of warrant liability           194,901          
Fair value     58,640 4,950 $ 4,830 58,640 4,950 $ 93,565   $ 5,550 $ 5,050
Change in fair value     (34,925) (100)   (141,811) 120        
Private Placement                      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Proceeds from warrant exercises $ 69,400                    
Private Placement | Subsequent Event                      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Class of warrant or right, exercised (in shares) | shares   10,026,847                  
AVTX-501                      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Maximum aggregate milestone payment         20,000            
AVTX-007 | Milestone One                      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Maximum aggregate milestone payment         6,250            
AVTX-007 | Milestone Two                      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Maximum aggregate milestone payment         67,500            
AVTX-611                      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Maximum aggregate milestone payment         20,000            
Derivative liability | Level 3                      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Initial valuation of warrant liability           0          
Fair value     11,810 4,950 4,830 11,810 4,950 $ 10,710   $ 5,550 $ 5,050
Change in fair value     $ 1,100 $ (100)   6,260 $ 120        
Derivative liability | AVTX-501                      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Initial valuation of warrant liability         $ 3,500 4,000          
Derivative liability | AVTX-501 | Measurement Input, Probability Of Success                      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Derivative liability, measurement input         0.23            
Derivative liability | AVTX-501 | Term (in years)                      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Derivative liability, measurement input, term         3 years 1 month 6 days            
Derivative liability | AVTX-007                      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Initial valuation of warrant liability         $ 1,300 $ 7,800          
Derivative liability | AVTX-007 | Measurement Input, Probability Of Success                      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Derivative liability, measurement input         0.17            
Derivative liability | AVTX-007 | Term (in years)                      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Derivative liability, measurement input, term         6 years 3 months 18 days            
Derivative liability | AVTX-007 | Measurement Input, Sales Forecast Peak                      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Net proceeds from the sale         $ 1,800,000            
Derivative liability | AVTX-501 And AVTX-007                      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Initial valuation of warrant liability         4,800            
ES Therapeutics, LLC | Derivative liability                      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Initial valuation of warrant liability         $ 5,000            
Warrant liability | Private Placement                      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Sale of stock (in shares) | shares 11,967,526                    
Warrants outstanding (in shares) | shares     11,967,526     11,967,526          
Warrant liability | Private Placement | Subsequent Event                      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Proceeds from warrant exercises   $ 58,100                  
Series C Preferred Stock | Private Placement                      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Sale of stock (in shares) | shares 19,946